STOCK TITAN

[Form 4] STERIS plc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Daniel A. Carestio, who serves as President and CEO and a Director of STERIS plc (STE), reported a Section 16 transaction dated 10/01/2025. On that date 289 restricted ordinary shares that had been awarded on 10/01/2021 vested and 130 of those vested shares were withheld to satisfy tax withholding obligations, leaving the reporting person with 51,255 ordinary shares beneficially owned following the transaction. The filing states that 33,054 ordinary shares remain restricted with scheduled lapse dates in June 2026, June 2027, and June 2028, and specifies the exact tranche amounts and dates for those restrictions.

Daniel A. Carestio, che ricopre il ruolo di Presidente e CEO e di Direttore di STERIS plc (STE), ha riportato una transazione di Sezione 16 datata 10/01/2025. In quella data 289 azioni ordinarie vincolate che erano state assegnate il 10/01/2021 hanno maturato e 130 di queste azioni maturate sono state trattenute per soddisfare gli obblighi di trattenimento fiscale, lasciando al soggetto che segnala la proprietà finale di 51,255 azioni ordinarie detenute beneficiariamente a seguito della transazione. La dichiarazione indica che 33,054 azioni ordinarie rimangono vincolate con date di scadenza programmate in giugno 2026, giugno 2027 e giugno 2028, e specifica gli importi esatti delle tranche e le relative date di restrizioni.

Daniel A. Carestio, quien se desempeña como Presidente y CEO y Director de STERIS plc (STE), informó de una transacción de la Sección 16 con fecha 01/10/2025. En esa fecha 289 acciones ordinarias restringidas que habían sido otorgadas el 01/10/2021 se adjudicaron y 130 de esas acciones adjudicadas se retuvieron para satisfacer las obligaciones de retención de impuestos, dejando al informante con 51,255 acciones ordinarias beneficiosamente poseídas tras la transacción. El registro indica que 33,054 acciones ordinarias siguen restringidas con fechas de vencimiento programadas en junio de 2026, junio de 2027 y junio de 2028, y especifica los montos exactos de los tramos y las fechas para esas restricciones.

Daniel A. CarestioSTERIS plc (STE)회장 겸 CEO이자 이사로 재직하며, 2025년 10월 1일로 기재된 섹션 16 거래를 보고했습니다. 그 날짜에 2021년 10월 1일에 부여된 289주의 제한 보통주가 취득했고, 그 중 130주가 세금 원천징수 의무를 충족하기 위해 제지되어 보고자에게 거래 후 실질적으로 보유하게 되는 보통주 수는 51,255주입니다. 신고서는 33,054주의 보통주가 여전히 제한되어 있으며 만기일이 2026년 6월, 2027년 6월, 2028년 6월로 예정되어 있으며, 이러한 제한의 정확한 계열 금액과 날짜를 명시하고 있습니다.

Daniel A. Carestio, qui occupe le poste de Président et CEO et de Directeur de STERIS plc (STE), a déclaré une transaction de la Section 16 datée du 01/10/2025. À cette date 289 actions ordinaires restreintes qui avaient été attribuées le 01/10/2021 sont devenues acquises et 130 de ces actions acquises ont été retenues pour satisfaire les obligations de retenue d’impôt, laissant le déclarant détenir 51 255 actions ordinaires bénéficiaires après la transaction. Le dépôt indique que 33 054 actions ordinaires restent restreintes avec des dates d’échéance prévues en juin 2026, juin 2027 et juin 2028, et précise les montants exacts des tranches et les dates correspondantes pour ces restrictions.

Daniel A. Carestio, der als Präsident und CEO sowie Direktor von STERIS plc (STE) fungiert, meldete eine Section-16-Transaktion mit dem Datum 01.10.2025. An diesem Datum reiften 289 eingeschränkte Stammaktien, die am 01.10.2021 zugeteilt worden waren, und 130 dieser verringerten Aktien wurden einbehalten, um die Steuerabzüge zu erfüllen, wodurch dem meldenden Personen nach der Transaktion 51.255 Stammaktien im wirtschaftlichen Eigentum verbleiben. Die Einreichung besagt, dass 33.054 Stammaktien weiterhin eingeschränkt bleiben mit geplanten Verfallterminen in Juni 2026, Juni 2027 und Juni 2028, und gibt die genauen Tranche-Beträge und Daten für diese Beschränkungen an.

دانيال أ. كارستيّو، الذي يشغل منصب الرئيس التنفيذي و مدير في STERIS plc (STE)، أبلغ عن صفقة من القسم 16 بتاريخ 01/10/2025. في ذلك التاريخ بلغت 289 سهماً عادية مقيدة كانت مُمنوحة في 01/10/2021 وتمّت vesting، و130 من تلك الأسهم المُكتسبة حُجِزت لتلبية التزام الاحتجاز الضريبي، مما ترك للمبلغ المبلغ عنه 51,255 سهماً عادية مُقيدًا يملكها المستفيدون بعد المعاملة. وتذكر العريضة أن 33,054 سهماً عاديًا بقي مقيداً مع تواريخ انقضاء مقررة في يونيو 2026، يونيو 2027 ويونيو 2028، وتحدد المبالغ الدقيقة للشرائح وتواريخها لهذه القيود.

Daniel A. Carestio,他担任 STERIS plc (STE)总裁兼首席执行官董事,报告了一笔日期为 2025-10-01 的第16条款交易。在该日期,授予于 2021-10-01289 股受限普通股已归属,且其中的 130 股已经归属但因税收扣缴义务而被扣留,使申报人交易后实际持有的普通股为 51,255 股。备案显示,仍有 33,054 股普通股受限,预定的失效日期为 2026年6月2027年6月2028年6月,并具体列出这些限制的各分阶段金额和日期。

Positive
  • Disclosure filed timely showing transparency about insider holdings and vesting
  • Detailed vesting schedule provided for 33,054 remaining restricted shares
Negative
  • 130 vested shares were withheld to satisfy tax obligations, reducing net vested shares

Insights

TL;DR: CEO reported vesting of 289 RSUs with 130 shares withheld for taxes; 51,255 shares now owned.

The Form 4 shows a routine equity vesting event for Daniel A. Carestio on 10/01/2025. The filing records that 289 restricted shares vested and 130 of those vested shares were withheld by the issuer to cover tax withholding obligations, a common administrative action following vesting.

The filing also discloses the remaining restricted balance of 33,054 shares and provides specific lapse dates and tranche sizes in June 2026, June 2027, and June 2028, which documents future potential dilution timing and the vesting schedule for insiders.

Daniel A. Carestio, che ricopre il ruolo di Presidente e CEO e di Direttore di STERIS plc (STE), ha riportato una transazione di Sezione 16 datata 10/01/2025. In quella data 289 azioni ordinarie vincolate che erano state assegnate il 10/01/2021 hanno maturato e 130 di queste azioni maturate sono state trattenute per soddisfare gli obblighi di trattenimento fiscale, lasciando al soggetto che segnala la proprietà finale di 51,255 azioni ordinarie detenute beneficiariamente a seguito della transazione. La dichiarazione indica che 33,054 azioni ordinarie rimangono vincolate con date di scadenza programmate in giugno 2026, giugno 2027 e giugno 2028, e specifica gli importi esatti delle tranche e le relative date di restrizioni.

Daniel A. Carestio, quien se desempeña como Presidente y CEO y Director de STERIS plc (STE), informó de una transacción de la Sección 16 con fecha 01/10/2025. En esa fecha 289 acciones ordinarias restringidas que habían sido otorgadas el 01/10/2021 se adjudicaron y 130 de esas acciones adjudicadas se retuvieron para satisfacer las obligaciones de retención de impuestos, dejando al informante con 51,255 acciones ordinarias beneficiosamente poseídas tras la transacción. El registro indica que 33,054 acciones ordinarias siguen restringidas con fechas de vencimiento programadas en junio de 2026, junio de 2027 y junio de 2028, y especifica los montos exactos de los tramos y las fechas para esas restricciones.

Daniel A. CarestioSTERIS plc (STE)회장 겸 CEO이자 이사로 재직하며, 2025년 10월 1일로 기재된 섹션 16 거래를 보고했습니다. 그 날짜에 2021년 10월 1일에 부여된 289주의 제한 보통주가 취득했고, 그 중 130주가 세금 원천징수 의무를 충족하기 위해 제지되어 보고자에게 거래 후 실질적으로 보유하게 되는 보통주 수는 51,255주입니다. 신고서는 33,054주의 보통주가 여전히 제한되어 있으며 만기일이 2026년 6월, 2027년 6월, 2028년 6월로 예정되어 있으며, 이러한 제한의 정확한 계열 금액과 날짜를 명시하고 있습니다.

Daniel A. Carestio, qui occupe le poste de Président et CEO et de Directeur de STERIS plc (STE), a déclaré une transaction de la Section 16 datée du 01/10/2025. À cette date 289 actions ordinaires restreintes qui avaient été attribuées le 01/10/2021 sont devenues acquises et 130 de ces actions acquises ont été retenues pour satisfaire les obligations de retenue d’impôt, laissant le déclarant détenir 51 255 actions ordinaires bénéficiaires après la transaction. Le dépôt indique que 33 054 actions ordinaires restent restreintes avec des dates d’échéance prévues en juin 2026, juin 2027 et juin 2028, et précise les montants exacts des tranches et les dates correspondantes pour ces restrictions.

Daniel A. Carestio, der als Präsident und CEO sowie Direktor von STERIS plc (STE) fungiert, meldete eine Section-16-Transaktion mit dem Datum 01.10.2025. An diesem Datum reiften 289 eingeschränkte Stammaktien, die am 01.10.2021 zugeteilt worden waren, und 130 dieser verringerten Aktien wurden einbehalten, um die Steuerabzüge zu erfüllen, wodurch dem meldenden Personen nach der Transaktion 51.255 Stammaktien im wirtschaftlichen Eigentum verbleiben. Die Einreichung besagt, dass 33.054 Stammaktien weiterhin eingeschränkt bleiben mit geplanten Verfallterminen in Juni 2026, Juni 2027 und Juni 2028, und gibt die genauen Tranche-Beträge und Daten für diese Beschränkungen an.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Carestio Daniel A

(Last) (First) (Middle)
70 SIR JOHN ROGERSON'S QUAY

(Street)
DUBLIN 2 L2 D02 R296

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 10/01/2025 F 130(1) D $0 51,255(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. 130 shares were withheld from the 289 restricted shares that vested on October 1, 2025. These 130 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 289 ordinary shares were awarded to Mr. Carestio on October 1, 2021. These vested shares were valued at the NYSE closing market price on October 1, 2025.
2. As of October 1, 2025, 33,054 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 4,308 on June 1, 2026; 5,937 on June 3, 2026; 2,369 on June 2, 2026; 4,283 on June 4, 2026; 5,937 on June 3, 2027; 4,283 on June 4, 2027; and 5,937 on June 5, 2028.
Remarks:
/s/ John P. Ubbing, Authorized Representative under Power of Attorney 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for STERIS (STE)?

Daniel A. Carestio, President and CEO and a Director, filed the Form 4.

What transaction is reported on the Form 4 dated 10/01/2025?

On 10/01/2025, 289 restricted ordinary shares vested and 130 of those shares were withheld for taxes.

How many shares does the reporting person beneficially own after the transaction?

The filing reports 51,255 ordinary shares beneficially owned following the reported transaction.

How many restricted shares remain and when do they vest?

As of 10/01/2025, 33,054 restricted shares remain with tranche lapse dates in June 2026, June 2027, and June 2028 and specified tranche amounts.

Why were shares withheld in this filing?

The filing states 130 shares were withheld to satisfy tax withholding obligations as determined by the issuer.
Steris Plc

NYSE:STE

STE Rankings

STE Latest News

STE Latest SEC Filings

STE Stock Data

23.70B
98.18M
0.3%
97.19%
0.82%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
DUBLIN